Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

NIH

Sponsor class

Conditions

Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
Metastatic Prostate Neuroendocrine Carcinoma
Metastatic Prostate Small Cell Neuroendocrine Carcinoma
Stage IV Prostate Cancer AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
RADIATION: Gallium Ga 68-DOTATATE
DRUG: Lutetium Lu 177 Dotatate
PROCEDURE: Positron Emission Tomography

Sponsor

National Cancer Institute (NCI)